Progression of temporal processing deficits in the HIV-1 transgenic rat

Kristen A. McLaurin, Rosemarie M. Booze & Charles F. Mactutus

The HIV-1 transgenic (Tg) rat, which expresses 7 of the 9 HIV-1 genes, was used to investigate the effect(s) of long-term HIV-1 viral protein exposure on chronic neurocognitive deficits observed in pediatric HIV-1 (PHIV). A longitudinal experimental design was used to assess the progression of temporal processing deficits, a potential underlying dimension of neurocognitive impairment in HIV-1. Gap prepulse inhibition (gap-PPI), a translational experimental paradigm, was conducted every thirty days from postnatal day (PD) 30 to PD 180. HIV-1 Tg animals, regardless of sex, displayed profound alterations in the development of temporal processing, assessed using prepulse inhibition. A differential sensitivity to the manipulation of interstimulus interval was observed in HIV-1 Tg animals in comparison to control animals. Moreover, presence of the HIV-1 transgene was diagnosed with 90.8% accuracy using measures of prepulse inhibition and temporal sensitivity. Progression of temporal processing deficits in the HIV-1 Tg rat affords a relatively untapped opportunity to increase our mechanistic understanding of the role of long-term exposure to HIV-1 viral proteins, observed in pediatric HIV-1, in the development of chronic neurological impairment, as well as suggesting an innovative clinical diagnostic screening tool.

Despite the success of combination antiretroviral therapy (cART) in diminishing the prevalence of progressive HIV-1 encephalopathy (PHE), high rates of chronic neurological impairment are still being reported in HIV-1 seropositive children1–4. Approximately 3.2 million children [≤ 15 years of age]5 are currently living with HIV-1; however, neurocognitive deficits in HIV-1 seropositive children, including disease progression, are poorly understood. The HIV-1 transgenic (Tg) rat may be used to model the effects of long-term HIV-1 viral protein exposure on the development and progression of chronic neurological deficits observed in children perinatally infected with HIV-16. The HIV-1 Tg rat, originally developed by Reid et al7, is non-infectious, expresses 7 of the 9 HIV-1 genes, and exhibits many clinical phenotypes (i.e. cataracts, low body weight) seen in HIV-1 seropositive individuals on cART8. Therefore, a longitudinal analysis of temporal processing deficits, a potential underlying dimension of neurocognitive impairment in HIV-1, may provide insight into the effect of long-term HIV-1 viral protein exposure on the development of chronic neurologic impairment in HIV-1 seropositive children.

Deficits in temporal processing, caused by HIV-1, may manifest prior to early symptoms of impairment in higher level cognitive processes9–12. Temporal processing deficits are commonly assessed using translational experimental paradigms, including prepulse inhibition (PPI) of the auditory startle response [ASR; refs 13, 14]. PPI involves two stimuli: a punctate prestimulus or prepulse (i.e., a light or a tone) and a startle stimulus15. Presentation of a prepulse 30–500 msec prior to the startle stimulus, causes dramatic reductions in the ASR15,16. Specifically, the degree to which the ASR is inhibited by the prepulse is dependent upon the interstimulus interval (ISI), the time interval between the prepulse and the startle stimulus. Use of PPI of the ASR, a behavioral approach, may elucidate the underlying mechanisms of more complex neurological processes17.

Alterations in temporal processing observed in the HIV-1 Tg rat have been observed in multiple preclinical models of HIV-1, as well as HIV-1 seropositive humans. Specifically, deficits in temporal processing have been observed in Sprague-Dawley rats stereotaxically injected with the HIV-1 viral proteins Tat and/or gp120. Neonatal (postnatal day (PD) 1) intrahippocampal Tat injections flattened the ISI function in auditory PPI, causing a shift in maximum peak inhibition18,19. A shift in the maximal peak inhibition for auditory PPI was also reported in 9-month old male and female Sprague-Dawley rats neonatally (PD 1) injected with gp12018. Temporal processing deficits have also been observed in SIV and FIV positive animals20–22, as well as HIV-1 seropositive individuals meeting criteria for HIV-1 associated neurocognitive disorders (HAND)11.

Analyses in the HIV-1 Tg rat have provided additional evidence that temporal processing deficits may be a potential underlying dimension of neurocognitive impairment in HIV-1. Cross-modal PPI was conducted in HIV-1 Tg and control rats between two and six months of age12. HIV-1 Tg animals, in comparison to control
animals, exhibited significant alterations in the development of temporal processing, evidenced by a relative insensitivity to the manipulation of ISI on both visual and auditory prepulse trials and a lack of perceptual sharpening with age. The generalizability of temporal processing deficits in the HIV-1 Tg rat, assessed using cross-modal PPI, were extended to animals at a more advanced age (i.e., 9, 10 months of age). HIV-1 Tg animals exhibited a relative insensitivity to the manipulation of ISI in both auditory and visual PPI. Consistent observations of temporal processing deficits regardless of the agent (i.e., single proteins, HIV, SIV, FIV, and the HIV-1 Tg rat) used to study neurocognitive deficits provide ample evidence for the critical importance of understanding the progression of these deficits using a longitudinal experimental design, as was the purpose of the present study.

Lesioning [i.e., ref. 24] and electrical stimulation studies [i.e., refs 25, 26] suggest that PPI of the ASR is mediated through a well-defined serial circuit. Excitatory input from the auditory pathway relays information to the inferior colliculus (IC), while input from the visual or tactile pathway relays information to the superior colliculus (SC). From the SC, sensory input subsequently activates the pedunculopontine tegmental nucleus (PPTg), triggering a cholinergic projection to the caudal pontine reticular nucleus (PnC) mediating PPI of the ASR. Activation of the PnC is relayed to motor neurons causing a startle response. Additionally, previous studies have established the hierarchical regulation of PPI, commonly abbreviated as the "CSPP circuitry," which is comprised of both sequential and parallel neural connections.

Gap-PPI is another translational experimental paradigm for sensorimotor gating that may be used to study temporal processing deficits. Specifically, in gap-PPI the absence of a background stimulus (relative to the presentation of an added stimulus) serves as the punctate prestimulus. Significant reductions in startle amplitude have been observed when a gap in background noise occurs between 30 and 200 msec prior to the startling stimulus. Analyses of gap-PPI in HIV-1 Tg rat at an advanced age (i.e., 9, 10 months of age) revealed a differential sensitivity to the manipulation of ISI. Specifically, control animals exhibited maximal inhibition at the 50 msec ISI, while HIV-1 Tg animals displayed a rightward shift, to maximal inhibition at the 100 msec ISI. Additionally, gap-PPI has been used as an innovative paradigm for studies of tinnitus in animals, including guinea pigs, mice and rats, providing proof-of-concept for the utility of gap-PPI as a translational diagnostic tool for tinnitus in humans. Subsequently, the gap startle paradigm was employed in adult humans with tinnitus offering new insight into the underlying neural mechanisms involved in tinnitus. Use of the gap-PPI experimental paradigms in HIV-1 seropositive children, therefore, may not only serve as a screening tool for chronic neurological impairment in pediatric HIV-1, but may also offer insight into the underlying neural mechanisms implicated in HIV-1.

Modeling the progression of neurocognitive deficits in the HIV-1 Tg rat is fundamental to the advancement of our knowledge of pediatric HIV-1 and as well as to the long-term HIV-1 viral protein exposure present in successful cART-treated individuals with HAND. Thus, the aims of the present study were threefold. First, using a longitudinal experimental design, establish the progression of temporal processing deficits using the gap-PPI experimental paradigm in the HIV-1 Tg rat. All animals were tested at 30 day intervals beginning at postnatal day (PD) 30. Second, to investigate the role of sex in the progression of temporal processing deficits in HIV-1; both male and female animals were integral to the experimental design. Thirdly, to assess the ability of gap-PPI to correctly classify animals in regard to their genotype based on measures of prepulse inhibition and temporal sensitivity. Progression of temporal processing deficits in the HIV-1 Tg rat affords a relatively untapped opportunity to increase our mechanistic understanding of the role of long-term exposure to HIV-1 viral proteins, such as seen in pediatric HIV-1 (PHIV), in the development of chronic neurological impairment, as well as suggesting an innovative clinical diagnostic screening tool.

**Methods**

Progression of temporal processing deficits in the HIV-1 Tg rat was assessed using a longitudinal analysis of gap-PPI. Alterations in the development of temporal processing were explored using a 2(genotype) × 2(sex) × 6(age) × 6(ISI) × 6(trial) mixed-factor design. A discriminant function analysis was conducted to determine the diagnostic accuracy, and potential translational relevance, of gap-PPI.

**Animals.** A longitudinal analysis of gap-PPI was conducted using intact Fischer (F344/N; Harlan Laboratories Inc., Indianapolis, IN) rats (Male HIV-1 Tg, n = 26; Female HIV-1 Tg, n = 22; Male Control, n = 20; Female Control, n = 19). Animals were tested for gap-PPI beginning at PD 30 and retested every thirty days at PD 60, PD 90, PD 120, PD 150, and PD 180. Animals were delivered to the facility between PD 7 and PD 9 over the course of four months. All animals were housed with their biological dam until PD 21 when animals were weaned and separated by sex. Subsequently animals were pair- or group-housed with animals of the same sex throughout development. Rodent food (Pro-Lab Rat, Mouse, Hamster Chow #3000) and water were provided ad libitum through 60 days of age. Pareticularly, all animals were subsequently under food restriction (85% body weight) due to their participation in a subsequently conducted signal detection task.

Animals were maintained according to the National Institutes of Health (NIH) guidelines in AAALAC-accredited facilities. The targeted environmental conditions for the animal facility were 21±2°C, 50±10% relative humidity and a 12:12-h light:dark cycle with lights on at 0700 h (EST). The Institutional Animal Care and Use Committee (IACUC) of the University of South Carolina approved the project protocol as consistent with federal assurance (# A3049-01).

**Apparatus.** The startle platform (SR-Lab Startle Reflex System, San Diego Instruments, Inc., San Diego, CA) was enclosed in a 10 cm-thick double-walled, 81×81×116-cm isolation cabinet (external dimensions) (Industrial Acoustic Company, Inc., Bronx, NY), instead of the 1.9 cm thick ABS plastic or laminate cabinets offered with this system. Sound attenuation of 30dB (A) was provided in the isolation chamber relative to the external environment. An ambient sound level of 22dB (A) was presented in the chamber without any stimuli presented. The high-frequency loudspeaker of the SR-Lab system (model #40-1278B, Radio Shack, Fort Worth, TX), mounted
inside the chamber 30 cm above the Plexiglas animal test cylinder, delivered all auditory stimuli (frequency range of 5k–16k Hz). The animal’s response to the auditory stimulus produced deflection of the test cylinder, which was converted into analog signals by a piezoelectric accelerometer integral to the bottom of the cylinder. The response signals were digitized (12 bit A to D) and saved to a hard disk. Response sensitivities were calibrated using a SR-LAB Startle Calibration System. Sound levels were measured and calibrated with a sound level meter (model #2203, Bruël & Kjaer, Norcross, GA) with the microphone placed inside the Plexiglas cylinder.

**Gap Prepulse Inhibition Assessments.** Intact Fischer rats (Male HIV-1 Tg, n = 26; Female HIV-1 Tg, n = 22; Male Control, n = 20; Female Control, n = 19) were tested for gap-PPI of the ASR beginning at PD 30. A 20-min test session began with a 5-min acclimation period in the dark with 70 dB(A) background white noise, followed by six pulse-only ASR trials, used for habituation, with a fixed 10 s intertrial interval (ITI). Thirty-six trials were presented using 6-trial blocks interdigitated using a Latin Square experimental design. Animals were tested with a 20-msec gap in white noise preceding a startle stimulus presented at ISIs of 30, 50, 100, and 200 msec. Two control trials, the 0 and 4000 msec ISI trials, were included to provide a reference ASR within gap-PPI. The startle stimulus intensity was 100 dB (A) (20 msec duration) measured inside the test cylinder. Mean peak ASR amplitude values were collected for analysis. All test sessions were conducted in the dark. Because it is well known that many stimulus parameters may influence the dependent measure of startle response amplitude, e.g., duration, intensity, frequency, etc., we choose (and held constant) stimulus parameters for robust prepulse inhibition, but that also would permit detection of increases or decreases in responding. We manipulated the fundamental factor that operationally defines prepulse inhibition, the ISI.

**Statistical Analyses.** Data were analyzed using analysis of variance (ANOVA) techniques (SPSS Statistics 20, IBM Corp., Somers, NY). Planned orthogonal contrasts or the post-hoc Greenhouse-Geisser df correction factor were used for potential violations of sphericity of within-subjects variables. Regression analyses and graphs were completed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). An alpha level of $p \leq 0.05$ was considered significant for all statistical tests.

The area of inflection of the ASR amplitude response curve, illustrated in Fig. 1 (i.e., shaded gray area), was calculated for each animal at every testing session as a measure of prepulse inhibition. A three-way mixed-factor ANOVA was performed on the mean area of peak inflection where genotype (HIV-1 Tg vs. control) and sex (male vs. female) served as the between-subjects factor. Age served as the within-subjects factor.

The ISI indexing the point of peak inflection for prepulse inhibition, as illustrated in Fig. 1, was also determined for each animal at every testing session. Specifically, a five-way mixed-factor ANOVA was performed on mean peak ASR amplitude for the 0–4000 msec ISIs as a measure of temporal sensitivity. Genotype (HIV-1 Tg vs. control) and sex (male vs. female) served as the between-subjects factor, while age, ISI, and trial served as the within-subjects factors.

The diagnostic accuracy of gap-PPI, i.e., the ability of the observed measures in gap-PPI to correctly identify animals in regard to their genotype (HIV-1 Tg vs. Control) was determined with a discriminant function analysis. Prepulse inhibition measurements (i.e., slope for the area of peak inflection, area of peak inflection at each test session) and temporal sensitivity (i.e., age at which a shift in maximum inhibition was observed) were included in the analysis. Slope for the area of peak inflection was calculated for each animal using the best-fit linear function.
Figure 2. (a) Prepulse inhibition, assessed using mean area of the peak inflection, is illustrated as a function of genotype (HIV-1 Tg or Control) and age (±95% CI). As age increases, control animals exhibit a linear increase in prepulse inhibition. Prepulse inhibition for HIV-1 Tg animals, however, was best fit using a one-phase association. Although control animals develop increased prepulse inhibition across age, HIV-1 Tg animals failed to exhibit an increase in prepulse inhibition after PD 90. Linear regression fit (R²): HIV-1 Tg, 0.96; Control, 0.99. (b) Prepulse inhibition for control animals is illustrated as a function of sex (Male or Female) and
Results

HIV-1 Tg rats exhibited a profound alteration in the progression of temporal processing assessed using prepulse inhibition. The progression of prepulse inhibition, assessed using mean area of the amplitude inflection, was altered in HIV-1 Tg animals in comparison to control animals (Fig. 2a). Prepulse inhibition for control animals was best fit using a first-order polynomial (R²: 0.99). In contrast, the best fit for HIV-1 Tg animals was a one-phase association (R²: 0.96). Control animals exhibited a significant development of temporal processing across age, while HIV-1 Tg animals failed to exhibit any significant progression of temporal processing after PD 90. The overall ANOVA on mean area of the amplitude inflection confirmed these observations, as revealed by a significant age x genotype interaction [F(5,415) = 6.3, pGG ≤ 0.001, η²_p = 0.22] and an increase in prepulse inhibition across age. However, there was a significant difference in the rate of increase in prepulse inhibition [F(1,230) = 4.3, p = 0.04], the variation of response amplitude by ISI for HIV-1 Tg animals in comparison to control animals.

Specifically, female control animals exhibited a significant increase in prepulse inhibition at 30 msec, while male control animals did not. The overall ANOVA for control animals confirmed these observations, as revealed by a significant main effect of age [F (1,83) = 21.0, p = 0.001, η²_p = 0.20] and sex [F (1, 83) = 19.4, p ≤ 0.001, η²_p = 0.19] were also present. Complementary results were obtained by conducting separate analyses of each genotype, illustrated in Fig. 2b (Control) and 2c (HIV-1 Tg). A first-order polynomial was the best fit for both male and female control animals (Male R²: 0.93; Female R²: 0.95), indicating an increase in prepulse inhibition across age. However, there was a significant difference in the rate of increase in prepulse inhibition [F(1,230) = 4.3, p ≤ 0.04]. The rate of temporal processing development was significantly greater in male control animals (β1: 1.824) in comparison to female control animals (β1: 1.820). The overall ANOVA for control animals confirmed these observations, as revealed by significant main effects of age [F(5,185) = 20.8, pGG ≤ 0.001, η²_p = 0.26] and sex [F(1,37) = 10.6, p ≤ 0.001, η²_f = 0.22]. In contrast, a one-phase association appeared to be the best fit function for both male and female HIV-1 Tg animals (Male R²: 0.92; Female R²: 0.82). No significant differences in prepulse inhibition were observed on PD 30. However, at PD 60 and all subsequent test dates, male HIV-1 Tg animals exhibited significantly greater prepulse inhibition in comparison to female HIV-1 Tg animals. The overall ANOVA for HIV-1 Tg animals confirmed these observations, as revealed by significant main effects of age [F(5,230) = 5.8, pGG ≤ 0.001, η²_p = 0.11] and sex [F(1,46) = 11.4, p ≤ 0.002, η²_p = 0.20]. Female HIV-1 Tg animals, therefore, may be more susceptible to the consequences of long-term HIV-1 viral protein exposure in comparison to male HIV-1 Tg animals. However, regardless of sex, prepulse inhibition provided little, if any, compelling evidence for normal development of temporal processing in the HIV-1 Tg rat.

HIV-1 Tg animals displayed a differential sensitivity to the manipulation of ISI. HIV-1 Tg animals displayed a differential sensitivity to the manipulation of ISI, as illustrated in Fig. 3a. A shift in maximal inhibition (from 30 msec to 50 msec) occurred in both the HIV-1 Tg and control animals; however, the shift occurred significantly earlier in the HIV-1 Tg animals. In the control group, a first-order polynomial (R²: 0.97) suggested peak inhibition was observed at the 30 msec ISI during the first three test periods (PD 30, PD 60 and PD 90), but that rightward shift to the 50 msec: ISI occurred during the latter three test periods (PD 120, PD 150 and PD 180). In contrast, the HIV-1 Tg group, well-described with a one-phase association (R²: 0.99), displayed peak inhibition at 30 msec during the first testing period (PD 30), but displayed a rightward shift during all later testing periods. The overall ANOVA revealed significant three-way interactions: genotype x age x ISI interaction [F(25,2050) = 11.1, pGG ≤ 0.001, η²_p = 0.12] and genotype x age x sex interaction [F(5,410) = 4.5, pGG ≤ 0.001, η²_p = 0.05], and an age x ISI x sex interaction [F(25,2050) = 4.4, pGG ≤ 0.001, η²_p = 0.05]. Second order interactions were also confirmed including: genotype x age x ISI interaction [F(5,410) = 54.4, pGG ≤ 0.001, η²_p = 0.40], an age x ISI interaction [F(25,2050) = 26.3, pGG ≤ 0.001, η²_p = 0.24], an age x sex interaction [F(5,410) = 10.2, pGG ≤ 0.001, η²_p = 0.11], an ISI x genotype interaction [F(5,410) = 7.1, pGG ≤ 0.001, η²_p = 0.08] and an ISI x sex interaction [F(5,410) = 23.3, pGG ≤ 0.01, η²_p = 0.22]. Significant main effects of age [F(5,410) = 68.3, pGG ≤ 0.001, η²_p = 0.45], ISI [F(5,410) = 164.9, pGG ≤ 0.001, η²_p = 0.67], genotype [F(5,82) = 100.7, p ≤ 0.001, η²_p = 0.55], and sex [F(5,82) = 40.6, p ≤ 0.001, η²_p = 0.33] were also noted. Clearly, there was a significantly greater effect of age on the variation of response amplitude by ISI for HIV-1 Tg animals in comparison to control animals.

Analyses of each genotype were conducted to further examine differences in the progression of temporal processing (Control: Fig. 3b; HIV-1 Tg: Fig. 3c). A first-order polynomial was a well-described fit for male control animals (R²: 0.98), while a one-phase association provided a well-described fit for female control animals (R²: 0.99). Specifically, female control animals exhibited a shift in maximal inhibition from 30 msec to 50 msec significantly earlier than male control animals. The overall ANOVA for control animals revealed an age x ISI x sex interaction [F(25,2900) = 2.9, pGG ≤ 0.001, η²_p = 0.08], an age x ISI interaction [F(25,2900) = 23.3, pGG ≤ 0.001, η²_p = 0.39], an age x sex interaction [F(5,180) = 7.2, pGG ≤ 0.001, η²_p = 0.11], and an ISI x sex interaction [F(5,180) = 12.0, pGG ≤ 0.001, η²_p = 0.26]. A significant main effect of age [F(5,180) = 62.8, pGG ≤ 0.001, η²_p = 0.64], ISI [F(5,180) = 111.4, pGG ≤ 0.001, η²_p = 0.76], and sex [F(3,160) = 16.0, p ≤ 0.001, η²_p = 0.31] were also revealed. In contrast, a one-phase association provided a well-described fit for both female and male HIV-1 Tg animals (R²: 0.99) suggesting that the shift in maximal inhibition from 30 msec to 50 msec was not dependent...
Figure 3. (a) The cumulative frequency for the shift in maximal inhibition from 30 msec to 50 msec is illustrated as a function of genotype (HIV-1 Tg or Control) and age (±95% CI). A shift in temporal processing occurred in both the HIV-1 Tg and control animals, however, the shift occurred significantly earlier in the HIV-1 Tg animals. A one-phase association was the best fit for HIV-1 Tg animals, while a first-order polynomial was the best fit for control animals. Linear regression fit (R²): HIV-1 Tg, 0.99; Control, 0.97. (b) The cumulative frequencies for the shift in maximal inhibition from 30 msec to 50 msec for control animals are illustrated as...
a function of sex (Male or Female) and age (±95% CI). Female control animals, which were fit using a one-phase association, exhibited a significantly earlier shift in maximal inhibition in comparison to control animals, which were best fit using a first-order polynomial. Linear regression fit (R²): Male, 0.98; Female, 0.99. (c) The cumulative frequencies for the shift in maximal inhibition from 30 msec to 50 msec for HIV-1 Tg animals are illustrated as a function of sex (Male or Female) and age (±95% CI). A one-phase association global fit was the best fit for both male and female HIV-1 Tg animals. Sex, therefore, did not have a significant effect on sensitivity to the manipulation of ISI in HIV-1 Tg animals. Linear regression fit (R²): 0.99.

upon sex in the presence of the HIV-1 transgene. The overall ANOVA for the HIV-1 Tg group did not reveal a significant age x sex interaction [F(5,230) = 1.7, pGG ≤ 0.146, η² = 0.04], nor a main effect of age [F(5,230) = 1.4, pGG ≤ 0.246, η² = 0.03], confirming these observations. Most notably, therefore, regardless of sex, HIV-1 Tg animals exhibited a significantly earlier shift in maximal inhibition, indicating a differential sensitivity to the manipulation of ISI.

Longitudinal gap-PPI can accurately diagnose the presence of the HIV-1 Transgene. Progression of temporal processing, assessed using gap-PPI, was further analyzed using a discriminant function analysis to determine the potential utility of gap-PPI as a diagnostic screening tool for chronic neurological impairment associated with the HIV-1 transgene. Transgene presence was best predicted using measures of prepulse inhibition (i.e., mean area of the peak inflection) and measures of temporal sensitivity (i.e., cumulative frequency), as illustrated in Fig. 4. Specifically, the discriminant function analysis selected four variables (slope of area of the peak inflection, area of the peak inflection at PD 180 and cumulative frequency at PD 60 and PD 180) that maximally separated the HIV-1 Tg and control animals (canonical correlation of 0.80). Animals were correctly diagnosed for the presence of the HIV-1 transgene with 90.8% accuracy (F approximation of Wilks’ λ of 0.368, F (4, 82) = 35.2, p ≤ 0.001).

Discussion

Prominent temporal processing deficits in the HIV-1 Tg rat were detected using the gap-PPI experimental paradigm. The developmental trajectory of prepulse inhibition, assessed using the gap-PPI experimental paradigm, was altered in the HIV-1 Tg rat relative to control animals, regardless of sex, from 30 to 180 days of age. Additionally, female HIV-1 Tg animals exhibited significantly less prepulse inhibition in comparison to male HIV-1 Tg animals. A differential sensitivity to the manipulation of ISI was also observed in the HIV-1 Tg rat, regardless of sex. Animals were correctly classified (90.8%) for the presence of the genotype (HIV-1 Tg or control) using measures of prepulse inhibition and temporal sensitivity. Temporal processing deficits observed in the HIV-1 Tg rat resemble those reported in HIV-1 seropositive individuals, providing insight into the effect of long-term exposure to HIV-1 viral proteins and the potential for development of a diagnostic screening tool for chronic neurological impairment.

HIV-1 Tg rats displayed a differential development of prepulse inhibition, assessed using the gap-PPI experimental paradigm, in a longitudinal experimental design. A one-phase association was the best fit for HIV-1 Tg animals, while a first-order polynomial was the best fit for control animals. No statistical differences in temporal processing between the HIV-1 Tg and control groups were observed at PD 30. However, significant differences in the progression of temporal processing, assessed using prepulse inhibition, were exhibited at subsequent testing sessions. Specifically, control animals displayed a linear increase in prepulse inhibition from PD 30 to PD 180. In contrast, HIV-1 Tg animals only exhibited a significant increase in prepulse inhibition from PD 30 to PD 90, after which point a plateau in temporal processing was observed. To our knowledge, the present study is the first to investigate the progression of temporal processing deficits using gap-PPI in the HIV-1 Tg rat, which is vital for the development of an extant model for HAND.

Sex differences in the progression of temporal processing deficits, assessed using prepulse inhibition, provide fundamental information for our understanding of the long-term effect of HIV-1 viral protein exposure in pediatric HIV-1. Both female HIV-1 Tg and control animals displayed significantly less prepulse inhibition, in comparison to male HIV-1 Tg and control animals, consistent with previous observations in healthy individuals. Regardless of sex, however, HIV-1 Tg animals exhibited significant alterations in temporal processing, assessed using prepulse inhibition; alterations which were more profound in female HIV-1 Tg animals in comparison to male HIV-1 Tg animals. Sex differences in the HIV-1 Tg rat expand on differences observed in HIV-1 seropositive individuals. Recent studies have reported significantly greater neurological impairment in HIV-1 seropositive women, in comparison to HIV-1 seropositive men. The effect of sex on the progression of neurocognitive impairments in HIV-1 seropositive individuals has been relatively understudied; the need for longitudinal study is critical.

A differential sensitivity to the manipulation of ISI was evidenced by a shift in the point of maximal inhibition. Both HIV-1 Tg and control animals displayed maximal inhibition at the 30 msec ISI on PD 30. However, HIV-1 Tg animals displayed a rightward shift in peak inhibition, from 30 msec to 50 msec, at PD 60. Notably, no sex differences were observed in the HIV-1 Tg animals. The point of maximal peak inhibition in control animals shifted from 30 msec to 50 msec at PD 120. Female control animals exhibited a significantly earlier shift in maximal inhibition in comparison to male control animals. Results of differential sensitivity to the manipulation of ISI in the present study extend those previously reported in the HIV-1 Tg rat and Sprague-Dawley rats stereotaxically injected with the HIV-1 viral proteins.

Temporal processing deficits observed using gap-PPI in the HIV-1 Tg rat may provide a novel screening tool for the diagnosis of chronic neurological impairment in pediatric HIV-1. A discriminant function analysis, used to evaluate the potential utility of gap-PPI, correctly identified animals in regards to their genotype (HIV-1 Tg
vs. control) with 90.8% accuracy. The presence of the HIV-1 transgene was best predicted using four variables as assessments of prepulse inhibition (i.e., slope of area of the peak inflection, area of the peak inflection at PD 180) and temporal sensitivity (i.e., cumulative frequency at PD 60 and PD 180). Gap-PPI was previously implicated as a novel screening tool for the diagnosis of tinnitus. Specifically, rats with noise over-expression-induced tinnitus33 or salicylate-induced tinnitus36 exhibited little to no inhibition in gap-PPI studies. The gap-PPI experimental paradigm was subsequently employed in adult humans with tinnitus offering new insight into the neural mechanisms of tinnitus37. Use of the gap-PPI experimental paradigms in HIV-1 seropositive humans, therefore, may not only serve as a screening tool for chronic neurological impairment in pediatric HIV-1, but may also offer insight into the underlying neural mechanisms implicated in HAND.

Clinical and preclinical studies have implicated disruptions in the development of the dopamine (DA) system as an underlying factor in neurocognitive impairments observed in pediatric HIV-146–50. A case study of five HIV-1 seropositive children observed improved motor function and activity with administration of levodopa (L-DOPA), a DA agonist51. In addition, pharmacological assessments have previously been used to examine alterations in the midbrain dopaminergic system in the HIV-1 Tg rat48,50. Dopaminergic system dysfunction, assessed using Western blotting, was evidenced by alterations in phosphorylated tyrosine hydroxylase (pTH), dopamine transporter (DAT) mRNA, and/or monoamine oxidase A [MAO-A; 48; 50]. In addition, young HIV-1 Tg rats exhibit deficits in D2/3 receptors in the dorsal striatum, assessed using [18F]fallypride positron emission tomography (PET)47.

DA system dysfunction may underlie temporal processing deficits observed in the HIV-1 Tg rat, as evidenced by previous behavioral and pharmacological studies52–54. Administration of direct (i.e., apomorphine) and indirect DA agonists (i.e., amphetamine) have been used to manipulate dopamine, subsequently disrupting PPI52. We have previously observed an insensitivity to the manipulation of ISI, assessed using cross-modal PPI, in rats administered apomorphine; results that are comparable to those observed in the HIV-1 Tg rat53 and schizophrenic patients55,56. Although temporal processing deficits observed in the HIV-1 Tg rat may be mediated by multiple neural systems, HIV-1 infection often affects DA system function and is associated with subsequent cognitive deficits55,58.

The potential role of oxidative stress and neuroinflammation as well as synaptodendritic injury are other potential mechanisms contributing to neurocognitive impairment in the HIV-1 Tg rat. Prior research has reported evidence of chronic immune activation in the brains of the HIV-1 Tg rat59,60. Thus, in the absence of viral replication, a chronic, mild, neuroinflammatory microenvironment exists in the HIV-1 Tg animals. Interestingly, the dopaminergic system appears to be particularly sensitive to neuroinflammatory degenerative processes61,62. Deficits in synaptic proteins as well as decreases in dendritic branching complexity and shifts in dendritic spine parameters have also been established63,64. HIV-1 associated neurocognitive disorders are thought to be the result of dendritic injury64 and synaptic dysfunction65.

The interpretation of the results presented herein and the longitudinal experimental design employed deserves further consideration. Prior longitudinal assessments of temporal processing provide evidence for experienced-based improvements66–68, a potential caveat for interpretation of the present study. However, assessments of gap-PPI in the present study began at PD 30, after the ontogeny of gap-PPI attains mature level (PD 28)66–69. Although the response amplitude per se may decrease as a function of experience66–68, there were no significant shifts in the ISI for peak inhibition in the amplitude response curve, which are observed in the present study as a function of age (i.e., Fig. 3). Critically, all animals in the present study were subjected to the same experiences during early development and immediately prior to experimentation; a level of control not present in studies with humans. As previously observed52, the protracted development of perceptual sharpening across repeated testing, as indexed by the relative insensitivity to ISI, may reflect, in part, impaired CNS plasticity in the HIV-1 Tg rat.
were able to detect the 20 msec visual stimulus presented. Thus, the current HIV-1 Tg rat displays a moderate similar inhibition in visual PPI suggesting that, despite the presence of cataracts in the HIV-1 Tg group, animals were observed in the HIV-1 Tg animals used in the current study. Both HIV-1 Tg and control animals display rates), consistent with our previous studies12,63,70. HIV-1 Tg animals used in the current study are a healthier der-

the progression of neurological impairment using a longitudinal experimental design. HIV-1 Tg rats used in

sensitivity, which may be a critical underlying dimension for the cognitive impairments observed in HAND. Thus, the use of a longitudinal experimental design and manipulation of ISI in gap-PPI affords an operationally defined factor for PPI to assess sensorimotor ‘gating’, i.e., a measure of temporal processing. The classical ISI approach is employed56, providing additional evidence that the present results are not an effect of experience. Thus, the study of early neurological deficits is vital for the development of an extant model for the progression of neurocognitive deficits in HAND, as well as the development of an effective treatment for pediatric HIV-1. The HIV-1 Tg rat, which resembles HIV-1 seropositive individuals on cART, provides a vehicle for understanding the progression of neurological impairment using a longitudinal experimental design. HIV-1 Tg rats used in the present study displayed no significant health disparities in comparison to F344 controls (i.e., similar growth rates), consistent with our previous studies12,63,70. HIV-1 Tg animals used in the current study are a healthier derivation of those originally described3, which displayed severe phenotypical alterations (e.g., hindlimb paralysis), and wasting at a relatively young age (5–9 months). In contrast, no general wasting or pathological phenotypes were observed in the HIV-1 Tg animals used in the current study. Both HIV-1 Tg and control animals display similar inhibition in visual PPI suggesting that, despite the presence of cataracts in the HIV-1 Tg group, animals were able to detect the 20 msec visual stimulus presented. Thus, the current HIV-1 Tg rat displays a moderate phenotype closely resembling HIV-1 seropositive children on cART, making it useful for longitudinal studies of HAND progression.

Temporal processing deficits observed in the HIV-1 Tg rat, assessed using gap-PPI, resemble temporal processing deficits commonly exhibited in HIV-1 seropositive individuals. Understanding the altered progression of temporal processing and differential sensitivity to the manipulation of ISI fills previous gaps in our knowledge about the effect of long-term exposure to HIV-1 viral proteins on neurocognitive impairment evident in pediatric HIV-1 and may reveal information regarding the underlying neural circuitry. Temporal processing measures suggest a diagnostic screening tool for chronic neurological impairment, as well as a venue for the development of novel therapeutics.

References
1. Franklin, S. et al. Longitudinal intellectual assessment of children with HIV infection. J Clin Psychol Med Settings 12, 367–376 (2005).
2. Parameswaran, Y. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving into adulthood. J Aquir Immune Defic Syndr 55, 134–136 (2010).
3. Smith, R. & Wilkins, M. Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead. Child Neuropsychol 21, 234–268 (2015).
4. Crowell, C. S., Maler, K. M., Yoge, R. & Muller, W. J. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. Rev Med Virol 24, 316–331 (2014).
5. Centers for Disease Control and Prevention., 23. McLaurin, K. A. In: End-of-life care for children with HIV infection: The medical, psychological, and social implications. In: End-of-life care for children with HIV infection: The medical, psychological, and social implications (2015).
6. Vigorito, M., Connaghan, K. P. & Chang, S. L. The HIV-1 transgenic rat model of neuroHIV. Brain Behav Immun 48, 336–349 (2015).
7. Reid, W. et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci USA 98, 9271–9276 (2001).
8. Peng, J. S. et al. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J Neuroimmunol 218, 94–101 (2010).
9. Castello E., Baroni N. & Pallestrini E. Neurotological and auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations. Ann Otol Rhinol Laryngol 107, 1054–1060 (1998).
10. Fitting, S., Bose, R. M. & Macutus, C. F. Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: Differential effects on behavior and the relationship to stereological hippocampal measures. Brain Res 1232, 139–154 (2008).
11. Minassian, A. et al. Prepulse inhibition in HIV-Associated Neurocognitive Disorders. J Int Neuropsychol Soc 19, 709–717 (2013).
12. Hoffman, H. S. & Seagle, J. L. Acoustic variables in modification of startle reaction in rat. J Comp Physiol Psychol 60, 53–58 (1965).
13. Ison, J. R. & Hammond, G. R. Modification of startle reflex in rat by changes in auditory and visual environments. J Comp Physiol Psychol 75, 435–452 (1971).
14. Hoffman, H. S. & Ison, J. R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87, 175–189 (1980).
15. Fitch, R. H., Threlkeld, S. W., McClure, M. M. & Peiffer, A. M. Use of a modified prepulse inhibition paradigm to assess complex auditory discriminability in rodents. Brain Res Bull 76, 1–7 (2008).
16. Fitting, S., Bose, R. M. & Macutus, C. F. Neonatal hippocampal Tat injections: Developmental effects on prepulse inhibition (PPI) of the auditory startle response. Int J Dev Neurosci 24, 275–283 (2006).
17. Fitting, S., Bose, R. M. & Macutus, C. F. Neonatal intrahippocampal glycocortipin 120 injection: The role of dopaminergic alteration in prepulse inhibition in adult rats. J Pharmacol Exp Ther 318, 1352–1358 (2006).
18. Fitting, S., Bose, R. M. & Macutus, C. F. Neonatal intrahippocampal glycocortipin 120 injection: The role of dopaminergic alteration in prepulse inhibition in adult rats. J Pharmacol Exp Ther 318, 1352–1358 (2006).
19. Huitron-Resendiz, S. et al. Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3. Journal of virology 78, 4525–4532 (2004).
20. Phipps, A. J., Hayes, K. A., Buck, W. R., Podell, M. & Mathes, L. E. Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. J Aquir Immune Defic Syndr 23, 8–16 (2000).
21. Prospero-Garcia, O. et al. Feline immunodeficiency virus envelope protein (FIVgpl20) causes electrophysiological alterations in rats. Brain Res 836, 203–209 (1999).
22. Raymond, L. A. et al. Auditory brainstem responses in a Rhesus Macaque model of neuro-AIDS. J Neurovirol 4, 512–520 (1998).
23. McLaurin, K. A. et al. A gap in time: Extending our knowledge of temporal processing deficits in the HIV-1 transgenic rat [abstract]. In: Society for Neuroscience. Abstract nr 4706, 12–16 Nov 2016.
24. Leitner, D. S. & Cohen, M. E. Role of the inferior colliculus in the inhibition of acoustic startle in the rat. Physiol Behav 34, 65–70 (1985).
25. Li, L., Priebe, P. M. & Yeomans, J. S. Prepulse inhibition of acoustic or trigeminal startle of rats by unilateral electrical stimulation of the inferior colliculus. Behav Neurosci 112, 1187–1198 (1998).
26. Li, L. & Yeomans, J. S. Using intracranial electrical stimulation to study the timing of prepulse inhibition of the startle reflex. Brain Res Protoc 5, 67–74 (2000).
27. Fendt, M., Köch, M. & Schnitzler, H. U. Sensorimotor gating deficit after lesions of the superior colliculus. NeuroReport 5, 1725–1738 (1994).
28. Fendt, M., Li, L. & Yeomans, J. S. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology 156, 216–224 (2001).
29. Köch, M., Kugel, M. & Herbert, H. Cholinergic neurons in the pedunculopontine tegmental nucleus are involved in the mediation of prepulse inhibition of the acoustic startle response in the rat. Exp Brain Res 97, 71–82 (1993).
30. Köch, M. & Schnitzler, H. U. The acoustic startle response in rats: Circuits mediating evocation, inhibition and potentiation. Behav Brain Res 89, 35–49 (1997).
31. Leitner, D. S. et al. Parameters affecting gap detection in the rat. Percept Psychophys 54, 395–405 (1993).
32. Ison, J. K., Agrawal, P., Pak, J. & Vaughn, W. J. Changes in temporal acuity with age and with hearing impairment in the mouse: a study of the acoustic startle reflex and its inhibition by brief decrements in noise level. J Acoust Soc Am 104, 1696–1704 (1998).
33. Dehmel, S., Eisinger, D. & Shore, S. E. Gap prepulse inhibition and auditory brainstem-evoked potentials as objective measures for tinnitus in guinea pigs. Front Systems Neurosci 6, 1–15 (2012).
34. Turner, J. G. et al. Gap detection deficits in rats with tinnitus: A potential novel screening tool. Behav Neurosci 120, 188–195 (2006).
35. Turner, J. G. & Parrish, J. L. Gap detection methods for assessing salicylate-induced tinnitus and hyperacusis in rats. Am J Audiol 17, 185–192 (2008).
36. Sun, W., Doolittle, L., Flowers, E., Zhang, C. & Wang, Q. High doses of salicylate causes prepulse facilitation of on-set-gap induced acoustic startle response. Behav Brain Res 258, 187–192 (2014).
37. Pournier, F. & Hebert, S. Gap detection deficits in humans with tinnitus as assessed with the acoustic startle paradigm: Does tinnitus fill in the gap? Hear Res 295, 16–23 (2013).
38. Greenhouse, S. W. & Geisser, S. On methods in the analysis of profile data. Psychometrika 24, 95–112 (1959).
39. Winer, B. J. Statistical Principles in Experimental Design (2nd ed.) New York: McGraw-Hill (1971).
40. Abel, K., Wacker, M., Pedro, B., Hemsley, D. & Geyer, M. Repeated testing of prepulse inhibition and habituation of the startle reflex: A study in healthy human controls. J Psychopharmacol. 12, 330–337 (1998).
41. Ornitz, E. M., Guthrie, D., Sadeghpour, M. & Sugiyama, T. Maturation of prestimulation-induced startle modulation in girls. Psychophysiology 28, 11–20 (1991).
42. Kumari, V., Aasen, I. & Sharma, T. Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophrenia Research 69, 219–235 (2004).
43. Royall, W. et al. Associations between cognition, gender and monocyte activation among HIV infected individuals in Nigeria. PLoS One 11, e0147182 (2016).
44. Hestad, K. A. et al. Sex differences in neuropsychological performance as an effect of human immuno deficiency virus infection: A pilot study in Zambia, Africa. J. Nerv. Ment. Dis. 200, 336–342 (2012).
45. Maki, P. M. et al. Cognitive function in women with HIV: Findings from the Women's Intergenricy HIV study. Neurology, 84, 231–240 (2015).
46. Fitting, S., Booze, R. M. & Machtutsus, C. F. HIV-1 proteins, Tat and gp120, target the developing dopamine system. J Neuroimmune Pharmacol 9, 508–521 (2014).
47. Webb, K. M., Aksenov, M. Y., Machtutsus, C. F. & Booze, R. M. Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 16, 168–173 (2010).
48. Mintz, M. Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes. Neurol 47, 1583–1585 (1996).
49. Geyer, M. A., Krebs-Thomson, K., Braff, D. L. & Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117–154 (2001).
50. Moran, L. M., Machtutsus, C. F. & Booze, R. M. General and resistance of prepulse inhibition by the dopamine agonist apomorphine. Behav Neurosci 128, 1253–1262 (2014).
51. Adler, L. E. et al. Neuropharmacology evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17, 639–654 (1982).
52. Braff, D. et al. Prestimulus effects on human startle reflex in normal and schizophrenics. Psychophysiology 15, 339–343 (1978).
53. De Rocca, A. et al. Decreased homovanillic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 23, 190–194 (2000).
54. Wang, G. et al. Decreased brain dopamine transporters in HIV-associated dementia patients. Brain 127, 2452–2458 (2004).
55. Rao, J. S. et al. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J Neuroinflammation 8, 101 (2011).
56. Royal, W. et al. Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J Neuroimmunol 247, 16–24 (2012).
57. Tansey, M. G. & Goldberg, M. S. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neuroblot. Dis 37, 510–518 (2010).
58. Gao, H.-M. et al. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 6768–6769 (2008).
59. Roscoe, R. F. Jr., Machtutsus, C. F. & Booze, R. M. HIV-1 transgenic female rat: Synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J Neuroimmune Pharmacol 9, 642–653 (2014).
60. Ellis, R., Langford, D. & Masliah, E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 8, 33–44 (2007).
61. Gelman, B. B. & Nguyen, T. P. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol. 5, 92–102 (2010).
62. Dean, K. F., Sheets, L. P., Crofton, K. M. & Reiter, L. W. The effect of age and experience on inhibition of the acoustic startle response by gaps in background noise. Psychobiology. 18, 89–95 (1990).
67. Threlkeld, S. W., Hill, C. A., Rosen, G. D. & Fitch, R. H. Early acoustic discrimination experience ameliorates auditory processing deficits in male rats with cortical developmental disruption. Int. J. Dev. Neurosci. 27, 321–328 (2009).
68. Friedman, J. T., Peiffer, A. M., Clark, M. G., Benasich A. & Fitch R. H. Age and experience-related improvements in gap detection in the rat. Dev. Brain Res. 152, 83–91 (2004).
69. Kellogg, C., Ison, J. R. & Miller, R. K. Prenatal diazepam exposure: Effects on auditory temporal resolution in rats. Psychopharmacology 79, 332–337 (1983).
70. Moran, L. M., Aksenov, M. Y., Booze, R. M., Webb, K. M. & Mactutus, C. F. Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr HIV-1 Res 10, 415–424 (2012).

Acknowledgements
This work was supported in part by grants from NIH (National Institute on Drug Abuse, DA013137; National Institute of Child Health and Human Development, HD043680; National Institute of Mental Health, MH106392) and the interdisciplinary research training program supported by the University of South Carolina Behavioral-Biomedical Interface Program. The authors acknowledge Hailong Li, MD, PhD, and Landhing M. Moran, PhD for critical reading of early drafts of the manuscript.

Author Contributions
R.M.B. and C.F.M. designed the study. K.A.M. planned the study, and collected and analyzed the behavioral data. K.A.M., R.M.B. and C.F.M. wrote the early drafts of the manuscript, and K.A.M. and C.F.M. updated and revised the final draft of the manuscript and figures and refined the statistical analyses. All authors read and approved the final version of the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: McLaurin, K. A. et al. Progression of temporal processing deficits in the HIV-1 transgenic rat. Sci. Rep. 6, 32831; doi: 10.1038/srep32831 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016